Navigation Links
Mesylate in Medical News

Gene signature may predict patient response to therapy for gastrointestinal stromal tumors

...r Center uncovered a genetic pattern that may help predict how gastrointestinal stromal tumor (GIST) patients respond to the targeted therapy imatinib mesylate (Gleevec). Moreover, their findings point to genes that could be suppressed in order to make these tumors respond more readily to imatinib. Lori R...

3-Drug Combo Reduces Nausea After Chemo

... Study finds adding casopitant mesylate to regimen cuts side effects MONDAY, M...thDay News) -- The addition of the drug casopitant mesylate (CM) to the conventional two-drug regimen of dexam...ee-day intravenous plus oral regimen of casopitant mesylate plus dexamethasone and ondansetron significantly r...

Enhancing the effects of the drug used to treat chronic myeloid leukemia

... might enhance the therapeutic effects of imatinib mesylate and other drugs that target the same molecule. ...ML cell lines and primary cells, although imatinib mesylate killed the majority of cells, a marked proportion ...nhibitors of autophagy might be used with imatinib mesylate or other drugs that target the same molecule to en...

JCI online early table of contents: April 13, 2009

... might enhance the therapeutic effects of imatinib mesylate and other drugs that target the same molecule. ...ML cell lines and primary cells, although imatinib mesylate killed the majority of cells, a marked proportion ...nhibitors of autophagy might be used with imatinib mesylate or other drugs that target the same molecule to en...

Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports

...he world. For more information, please visit http://www.us.novartis.com . References DeMatteo, R., et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. The Lancet. Published onl...

Combination of 2 novel anti-cancer agents may help fight CML resistant to current therapy

...tor for translational research and co-leader of the cancer centers cancer cell biology program, and senior author of the study, resistance to imatinib mesylate prompted the search for newer agents that are active against the mutated forms of Bcr/Abl. Such agents include MK-0457, a Bcr/Abl kinase inhibitor tha...

Protein predicts Gleevec resistance in gastrointestinal tumors

...n called IGF-1R in patients with gastrointestinal stromal tumors (GISTs) could indicate that the patient would be less responsive to the drug imatinib mesylate (known as Gleevec), according to Andrew K. Godwin, Ph.D., a researcher at the Fox Chase Cancer Center in Philadelphia. Preliminary studies have shown...

Actavis Extends Portfolio With Four New Products in the U.S.

...ciated with certain nerve disorders. Benztropine mesylate Tablets, 0.5mg, 1mg, 2mg: are the generic equivalent to Cogentin(R). Benztropine mesylate is an antidrykinetic, which reduces the symptoms o...nd reducing stiffness. Annual sales of Benztropine mesylate were US$12.8 million for the 12 months ending Dece...

Diuretics Best for Hypertension and Metabolic Syndrome

...mly assigned to take either the diuretic chlorthalidone (15,255), the calcium channel blocker amlodipine besylate (9,048), the alpha-blocker doxazosin mesylate (9,061), or the ACE inhibitor lisinopril (9,054). Each drug was used to start treatment, and other drugs were added if necessary to control blood p...

Photo: New Data Show Gleevec(R) Halts Progression to Advanced Stages of Life-Threatening Form of Leukemia in Sixth Year of Treatment

...er, 2007. 4. Hochhaus, A., Druker, B. et al. Favorable long-term follow-up results over six years for response, survival and safety with imatinib mesylate therapy in chronic phase chronic myeloid leukemia post failure of interferon alpha treatment. Blood, 2007. Media only: ...
Mesylate in Medical Technology

Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease

-- Exploratory study shows clinical improvement in patients with pulmonary arterial hypertension (PAH) -- Current treatment options have limited benefit for this debilitating, rapidly progressive and incurable blood vessel disease -- Imatinib mesylate, available as Gleevec(R)...

Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer

Phase II Data Presented at ASCO Showed Acceptable Tolerability Profile, with Low Incidence of Grade 3 and 4 Neuropathy WOODCLIFF LAKE, N.J., May 15 /PRNewswire/ -- The investigational chemotherapeutic agent eribulin mesylate (E7389) demonstrated activity in a heavily pretreated pop...

Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types

...ancer.gov/cancertopics/pdq/treatment/melanoma/HealthProfessional/page11 . Accessed May 2009. Carvajal RD, et al. A phase II study of Imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT. Abstract # 9001. American Society of Clinical Oncology 2009 Annual Meet...

Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery

...opinion http://www.emea.europa.eu/pdfs/human/opinion/Glivec_65949508en.pdf. Last accessed 7 May 2009 2. DeMatteo, R. et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. The Lancet. Online public...

More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies

...ata to be presented at ASH include: Gleevec A Phase III, Randomized, Open-Label Study of 400 Mg Versus 800 Mg of Imatinib mesylate in Patients with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Using Molecular Endpoints: 1-Year Results of...

MicroRNA First Disclosed by Rosetta Genomics may Increase Efficacy of Imatinib (Gleevec(R)(1)) in Glioblastoma

...de. Our first microRNA-based products, diagnosing various cancers, are expected to be launched later this year." In the study, "MIR-451 and Imatinib mesylate Inhibit the Growth of Glioblastoma Stem Cells", published online in Biochemical and Biophysical Research Communications, scientists demonstrated that ...

Journal of the American Dental Association Publishes Key Clinical Data for the Use of OraVerse(TM) a Local Anesthetic Reversal Agent

...scents and adults" includes an overview of two pivotal trials while the second publication "Reversal of soft-tissue local anesthesia with phentolamine mesylate in pediatric patients" reviews the pediatric Phase 2 data. Together these key Novalar-sponsored clinical trials were the foundation for the FDA approv...

US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings

...ncer Centers of Nevada-Siena and Joanne Blum, M.D., Ph.D., Texas Oncology-Baylor Charles A Sammons Cancer Center: Phase II study of eribulin mesylate in patients with locally advanced or metastatic breast cancer (MBC) previously treated with an anthracycline, taxane, and capecitabine -- ...

GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant)

...etic-risk chemotherapy. Support Care Cancer. 2005;13:85-96. (9) Arpornwirat W, Albert I, Hansen V, et. Al. In a Randomized Phase II Trial Casopitant mesylate + Ondansetron and Dexamethasone Reduced Chemotherapy-Induced Nausea/Vomiting (CINV) in Patients Receiving Moderately Emetogenic Chemotherapy (MEC). MA...

Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting

... Eribulin Phase II Study of Eribulin June 2, 2008 mesylate (E7389) mesylate (E7389) in Patients 2:00-6:00 p.m. Abstract No: 1084 with Local...
Mesylate in Biological News

Eribulin mesylate demonstrated anti-tumor activity in patients with advanced breast cancer

Woodcliff Lake, N.J., May 15, 2008The investigational chemotherapeutic agent eribulin mesylate (E7389) demonstrated activity in a heavily pretreated population of women with locally advanced or metastatic breast cancer, according to results of a multi-center Phase II clinical trial. The study als...

Landmark studies assess risk of exposure to elevated levels of EMS confirm clear toxicity threshold

... the toxicity of an impurity called ethyl methanesulfonate (EMS). The formation of the EMS impurity is a potential by-product of the manufacturing of mesylate salts, which are contained in over 40 drugs currently available worldwide. The studies were designed to determine the impact of elevated EMS level...
Mesylate in Biological Technology

ETHEX Corporation Issues Nationwide Voluntary Recall of Products

...te ER Capsules, 150mg (58177-002-04) Doxazosin mesylate Tablets, 1mg (58177-266-04 & 266-08) Doxazosin mesylate Tablets, 2mg (58177-267-04 & 267-08) Doxazosin mesylate Tablets, 4mg (58177-268-04 & 268-08) Doxaz...
Other Tags
(Date:7/31/2015)... ... 31, 2015 , ... Jacksonville-based drug and alcohol rehabilitation center, ... Center. The medical community, social workers, law enforcement, and government officials are all ... the effort to better understand and combat sex trafficking. Lead by sex trafficking ...
(Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a ... Those looking to catch a new and refreshing show on Broadway, look no further ... achievements including an Obie Award, Outer Critics Circle Award, Drama Desk Award, Lucille Lortel ...
(Date:7/31/2015)... New York (PRWEB) , ... ... ... trial attorney Jason T. Brown’s live lecture on pharmaceutical negligence is now ... 28th, 2015 was well received with a 94% approval rating from the ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Transfinder, a software ... , Total sales were up 16 percent year-over-year for the first six months ended ... Civitella said he expected Transfinder to beat last year’s record-revenue mark of $10.4 million. ...
(Date:7/31/2015)... ... July 31, 2015 , ... Mullin/Ashley Associates , ... the 2015 Aster Awards national competition for a marketing communications campaign created for ... surrounding communities in Coastal Maryland and Southern Delaware. , A Bronze Award was ...
Breaking Medicine News(10 mins):Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 2Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 3Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 4Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 5Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 6Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 7Health News:Re-Broadcast of Nationally Renowned Trial Attorney Jason T. Brown's Lecture on Pharmaceutical Negligence Now Available 2Health News:Transfinder Closes First Half of 2015 with Record Revenue 2Health News:Mullin/Ashley Associates Wins in the 2015 Aster Awards National Competition for Excellence in Medical Marketing 2
(Date:7/13/2015)... JOSE, Calif. , July 13, 2015 /PRNewswire/ ... leading developer of human interface solutions, today announced ... generation touch and display driver integration (TDDI) product ... is the first to combine Synaptics , ... with proven display driver technology developed in the ...
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), a ... it will report financial results for the fourth quarter ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
(Date:7/9/2015)... July 9, 2015  Unchained Labs just can,t ... acquisition of Avid Nano. Avid Nano designs, develops ... systems.    Also today, Unchained Labs ... easiest to use protein sizing system. The pUNk ... protein,s hydrodynamic size, size distribution, aggregation population and ...
Breaking Biology News(10 mins):Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2
Other Contents